Supplementary Material

Table S1. Expressions of pathological impulsivity. MedDRA query and behavioral subqueries used for retrieving drug-induced impulsivity.

Impulsivity expression	Preferred Terms (PT)				
Pathological gambling	gambling disorder, gambling				
Hypersexuality	compulsive sexual behaviour, hypersexuality, excessive				
	masturbation, excessive sexual fantasies, libido increased,				
	sexual activity increased, kluver-bucy syndrome				
Paraphilia	erotophonophilia, exhibitionism, fetishism, frotteurism,				
	masochism, paraphilia, pedophilia, sadism, transvestism,				
	voyeurism, sexually inappropriate behaviour				
Compulsive shopping	compulsive shopping				
Hyperphagia	binge eating, food craving, hyperphagia, increased appetite				
Gaming disorder	gaming disorder				
Pyromania	pyromania				
Kleptomania	kleptomania				
Compulsive hoarding	compulsive hoarding				
Excessive exercise	excessive exercise				
Overwork	overwork				
Poriomania	poriomania				
Body-focused repetitive	compulsive cheek biting, compulsive lip biting,				
behaviors	dermatillomania, dermatophagia, nail picking, compulsive				
	handwashing, trichotemnomania, trichotillomania,				
	onycophagia, thumb sucking				
Stereotypy	automatism, stereotypy				
Impulsivity	impulse-control disorder, impulsive behaviour,				
	disinhibition, behavioural addiction				

Table S2. Manifestation of impulsivity in the two populations investigated.

Prami	pexole	Aripip	razole
Gambling disorder	1345 (4.87%)	Gambling disorder	2067 (2.58%)
Hypersexuality	612 (2.22%)	Hypersexuality	1077 (1.34%)
Impulsivity	453 (1.64%)	Compulsive shopping	1029 (1.28%)
Compulsive shopping	384 (1.39%)	Hyperphagia	868 (1.08%)
Hyperphagia	334 (1.21%)	Impulsivity	730 (0.91%)
Stereotypy	87 (0.32%)	Body-focused disorder	316 (0.39%)
Paraphilia	64 (0.23%)	Compulsive hoarding	244 (0.30%)
Compulsive hoarding	26 (0.09%)	Paraphilia	78 (0.10%)
Body-focused disorder	18 (0.07%)	Stereotypy	42 (0.05%)
Excessive exercise	7 (0.03%)	Poriomania	15 (0.02%)
Kleptomania	7 (0.03%)	Kleptomania	6 (0.01%)
Gaming disorder	3 (0.01%)	Pyromania	4 (0.00%)
Poriomania	2 (0.01%)	Overwork	1 (0.00%
Pyromania	1 (0.00%)		

Table S3. Features of pramipexole reports. We compared cases of pramipexole-related pathological impulsivity vs any other report recording pramipexole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.

VARIABLE	Impulsi	vity Reports	Other Reports	p-value	
		N = 2,066	N = 25,535		
	N	%	N	%	
Gender					<0.001
Woman	821	42.58	14,964	63.01	
Man	1,107	57.42	8,784	36.99	
Unknown	138	-	1,787	-	
Age (years old)		56 (48-64)		67 (57-75)	<0.001
Unknown		903		8,482	
Weight (Kg)		83 (72-95)		79 (65-95)	<0.001
Unknown		1,386		16,330	
Outcome					<0.001
Death	40	1.94	1,883	7.37	
Life Threatening	50	2.42	713	2.79	
Disability	90	4.36	687	2.69	
Required Intervention	27	1.31	74	0.29	
Hospitalization	305	14.76	7,378	28.89	
Congenital	0	0.00	20	0.08	
Other Serious	627	30.35	6,205	24.30	
Non-Serious	927	44.87	8,575	33.58	
Reporter					<0.001
Consumer	1,092	56.73	10,315	44.75	
Healthcare practitioner	50	2.60	1,378	5.98	
Lawyer	29	1.51	220	0.95	
Other	380	19.74	3,366	14.60	
Pharmacist	29	1.51	1,822	7.90	
Physician	345	17.92	5,950	25.81	
Unknown	141	-	2,484	-	

Table S4. Features of aripiprazole reports. We compared cases of aripiprazole-related pathological impulsivity vs any other report recording aripiprazole. Chi-square test was performed for categorical values, Mann-Whitney for continuous ones, and p-values were corrected for multiple comparison using the Holm-Bonferroni method.

VARIABLE	Impuls	ivity Reports	Other Reports		p-value
		N = 3,609	N = 76,629		-
	N	%	N	%	
Gender					<0.001
Woman	1,624	51.41	40,454	59.28	
Man	1,535	48.59	27,792	40.72	
Unknown	450	-	8,383	-	
Age (years old)		40 (25-51)		41 (26-55)	<0.001
Unknown		1,951		25,267	
Weight (Kg)		82 (68-104)		79 (63-98)	<0.001
Unknown		2,876		55,594	
Outcome					<0.001
Death	31	0.86	4,099	5.35	
Life Threatening	61	1.69	2,823	3.68	
Disability	483	13.38	1,868	2.44	
Required Intervention	12	0.33	280	0.37	
Hospitalization	1,205	33.39	17,921	23.39	
Congenital	0	0.00	325	0.42	
Other Serious	896	24.83	21,051	27.47	
Non-Serious	921	25.52	28,262	36.88	
Reporter					<0.001
Consumer	1,416	40.18	34,977	48.55	
Healthcare practitioner	173	4.91	4,146	5.76	
Lawyer	1,201	34.08	790	1.10	
Other	256	7.26	10,795	14.98	
Pharmacist	45	1.28	4,159	5.77	
Physician	433	12.29	17,173	23.84	
Unknown	85	-	4,589	-	

Table S5. Events disproportionally reported with aripiprazole-induced impulsivity. Ordered by N.

Event	Perc (%)	Information Component Median (95%CI) [N]
acamamia medilam	37,85	
economic problem	33,19	4.28 (4.19-4.34) [1366]
obsessive-compulsive disorder		4.16 (4.07-4.23) [1198]
product use in unapproved indication	27,51	2.8 (2.69-2.87) [993]
Injury	25,10	4 (3.9-4.08) [906]
mental disorder	23,75	3.7 (3.59-3.78) [857]
suicidal ideation	23,47	2.69 (2.58-2.77) [847]
weight increased	23,19	1.83 (1.71-1.91) [837]
emotional distress	22,80	3.75 (3.63-3.83) [823]
Anxiety	21,56	2.2 (2.09-2.29) [778]
suicide attempt	21,50	2.99 (2.88-3.08) [776]
condition aggravated	20,34	2.91 (2.79-3) [734]
eating disorder	16,15	4.05 (3.92-4.15) [583]
Pain	14,35	2.45 (2.3-2.55) [518]
loss of employment	12,64	4.33 (4.18-4.44) [456]
Disability	11,42	3.79 (3.63-3.91) [412]
Anhedonia	10,94	3.75 (3.59-3.87) [395]
Bankruptcy	10,58	4.43 (4.26-4.55) [382]
Insomnia	8,04	1.13 (0.94-1.27) [290]
Divorced	7,59	4.38 (4.19-4.53) [274]
Homeless	6,93	4.37 (4.16-4.52) [250]
sexual dysfunction	6,79	3.25 (3.04-3.4) [245]
Depression	6,62	0.78 (0.57-0.94) [239]
Fatigue	6,62	0.78 (0.57-0.94) [239]
Theft	5,79	4.32 (4.09-4.48) [209]
Shoplifting	5,02	4.37 (4.12-4.54) [181]
neuropsychiatric symptoms	4,74	4.35 (4.1-4.53) [171]
Irritability	4,54	1.73 (1.47-1.91) [164]
Aggression	4,35	1.26 (1-1.45) [157]
Akathisia	4,05	0.89 (0.62-1.09) [146]
Somnolence	4,02	0.38 (0.1-0.57) [145]
Headache	4,02	0.51 (0.24-0.71) [145]
Restlessness	3,69	1.08 (0.79-1.28) [133]
Agitation	3,57	0.76 (0.47-0.97) [129]
abnormal behaviour	3,44	1.28 (0.98-1.49) [124]
Mania	3,13	1.11 (0.8-1.33) [113]
mental impairment	3,08	2.26 (1.95-2.49) [111]
sexually transmitted disease	3,05	4.24 (3.93-4.47) [110]
Hypertension	2,96	1.01 (0.69-1.24) [107]
Asthenia	2,96	0.89 (0.57-1.13) [107]
personal relationship issue	2,94	3.9 (3.58-4.13) [106]
Obesity	2,91	1.42 (1.1-1.66) [105]
weight decreased	2,72	0.79 (0.46-1.03) [98]
disturbance in attention	2,72	1.51 (1.17-1.75) [98]
feeling abnormal	2,72	0.37 (0.04-0.61) [98]
euphoric mood	2,69	3.02 (2.68-3.26) [97]
social problem	2,66	3.78 (3.45-4.03) [96]
memory impairment	2,60	1.05 (0.71-1.29) [94]
sleep disorder	2,60	1.53 (1.19-1.77) [94]
Diarrhoea	2,49	0.54 (0.19-0.8) [90]
therapeutic product effect incomplete	2,38	1.88 (1.52-2.14) [86]
depressed mood	2,36	1 11 1
brain injury	2,36	
Hyperhidrosis	2,27	
brain injury	2,36	1.68 (1.32-1.94) [85] 3.11 (2.75-3.37) [85] 0.91 (0.54-1.17) [82]

prazoie-induced impuisivity.	Jraerea	by IV.
Event	Perc (%)	Information Component Median (95%CI) [N]
sedation	2,24	0.72 (0.36-0.99) [81]
anger	2,19	1.39 (1.02-1.66) [79]
hallucination, auditory	2,13	0.63 (0.25-0.9) [77]
prescribed overdose	2,13	1.89 (1.52-2.17) [77]
constipation	2,11	0.83 (0.45-1.1) [76]
back pain	2,11	1.12 (0.74-1.39) [76]
blood glucose increased	2,08	0.73 (0.34-1) [75]
psychosexual disorder	2,02	4.1 (3.71-4.38) [73]
stress	2,00	1.9 (1.51-2.18) [72]
hospitalisation	2,00	0.68 (0.29-0.96) [72]
blood cholesterol increased	1,94	0.95 (0.55-1.23) [70]
arthralgia	1,88	0.78 (0.37-1.07) [68]
toxicity to various agents	1,83	0.48 (0.07-0.77) [66]
gastrooesophageal reflux disease	1,83	1.97 (1.57-2.27) [66]
fear	1,83	2.1 (1.69-2.4) [66]
decreased appetite	1,77	0.75 (0.34-1.05) [64]
hypoaesthesia	1,69	1.1 (0.68-1.41) [61]
antipsychotic drug level below therapeutic	1,66	3.69 (3.26-3.99) [60]
therapeutic product effect variable	1,63	4.06 (3.63-4.37) [59]
hypersomnia	1,61	1.61 (1.17-1.92) [58]
leukopenia	1,55	1.79 (1.35-2.11) [56]
drug dependence	1,55	1.88 (1.44-2.2) [56]
nightmare	1,50	1.87 (1.42-2.19) [54]
unintended pregnancy	1,50	3.71 (3.26-4.04) [54]
blood triglycerides increased	1,47	1.15 (0.69-1.48) [53]
cough	1,44	1.06 (0.6-1.39) [52]
poor quality sleep	1,36	2.25 (1.78-2.59) [49]
abdominal pain	1,36	0.74 (0.27-1.08) [49]
psychomotor hyperactivity	1,33	1.32 (0.84-1.66) [48]
paranoia	1,30	0.64 (0.15-0.98) [47]
gastrointestinal surgery	1,30	4.06 (3.57-4.41) [47]
migraine	1,27	1.2 (0.71-1.55) [46]
bipolar disorder	1,27	0.96 (0.47-1.31) [46] 1.23 (0.74-1.58) [46]
mood swings	1,27	3.12 (2.62-3.47) [45]
dyslipidaemia	1,25	
amnesia	1,25	0.8 (0.31-1.16) [45]
thinking abnormal affective disorder	1,19	0.86 (0.35-1.22) [43]
	1,19	1.96 (1.45-2.32) [43]
dyspepsia	1,16	1.8 (1.28-2.16) [42]
hunger	1,16	2.14 (1.63-2.51) [42]
sleep apnoea syndrome	1,16	1.3 (0.79-1.67) [42]
dependence	1,16	3.29 (2.78-3.66) [42]
myalgia .	1,14	0.55 (0.03-0.92) [41]
crying	1,14	0.81 (0.29-1.18) [41]
panic attack	1,14	1.03 (0.51-1.4) [41]
incorrect dose administered	1,14	0.69 (0.17-1.06) [41]
muscle twitching	1,11	0.79 (0.26-1.16) [40]
prescribed underdose	1,11	0.89 (0.37-1.27) [40]
personality disorder	1,08	2.66 (2.13-3.04) [39]
apathy	1,08	1.25 (0.71-1.63) [39]
alanine aminotransferase increased	1,08	1.05 (0.52-1.43) [39]
loss of personal independence in daily activities	1,05	1.12 (0.58-1.51) [38]
cognitive disorder	1,03	0.79 (0.25-1.18) [37]
low density lipoprotein increased	1,03	3.22 (2.67-3.61) [37]

Table S6. Events disproportionally reported with pramipexole-induced impulsivity. Ordered by N.

Event	Perc (%)	Information Component Median (95%CI) [N]
obsessive-compulsive disorder	26,77	3.47 (3.33-3.57) [553]
emotional distress	21,35	3.42 (3.26-3.54) [441]
Depression	20,67	2.43 (2.27-2.55) [427]
Pain	16,02	1.64 (1.45-1.77) [331]
Anxiety	13,79	1.93 (1.73-2.07) [285]
suicidal ideation	9,73	2.7 (2.47-2.87) [201]
weight increased	9,29	1.93 (1.7-2.11) [192]
Insomnia	7,12	0.79 (0.52-0.99) [147]
abnormal behaviour	6,73	2.52 (2.24-2.72) [139]
Somnolence	6,39	0.72 (0.43-0.92) [132]
economic problem	6,05	3.15 (2.85-3.36) [125]
Stress	5,86	2.5 (2.2-2.71) [121]
suicide attempt	5,28	2.74 (2.43-2.97) [109]
Dyskinesia	4,70	0.62 (0.28-0.86) [97]
Fear	4,65	2.95 (2.61-3.19) [96]
Injury	4,11	2.53 (2.17-2.78) [85]
Aggression	3,05	1.9 (1.48-2.2) [63]
personality change	2,66	2.93 (2.49-3.26) [55]
eating disorder	2,47	2.95 (2.49-3.28) [51]
Dependence	2,37	3.26 (2.79-3.6) [49]
hallucination, visual	2,37	0.69 (0.21-1.03) [49]
psychomotor hyperactivity	2,37	2.24 (1.76-2.58) [49]
dopamine dysregulation syndrome	2,32	2.72 (2.24-3.07) [48]
Overdose	2,27	1.27 (0.79-1.62) [47]
sleep disorder	2,23	1.07 (0.58-1.42) [46]
psychotic disorder	2,23	1.56 (1.06-1.91) [46]
Agitation	2,18	0.81 (0.32-1.17) [45]
mental disorder	2,13	2.24 (1.74-2.6) [44]

Event	Perc (%)	Information Component Median (95%CI) [N]
drug withdrawal syndrome	1,94	1.78 (1.26-2.16) [40]
drug dependence	1,94	2.34 (1.81-2.71) [40]
irritability	1,89	1.95 (1.42-2.33) [39]
drug abuse	1,89	2.46 (1.93-2.84) [39]
mania	1,84	2.02 (1.48-2.4) [38]
on and off phenomenon	1,79	0.87 (0.32-1.26) [37]
cognitive disorder	1,74	1.04 (0.48-1.43) [36]
compulsions	1,74	3.05 (2.49-3.44) [36]
sudden onset of sleep	1,74	1.61 (1.05-2) [36]
crying	1,60	1.86 (1.28-2.27) [33]
delusion	1,60	0.93 (0.35-1.34) [33]
apathy	1,45	2.7 (2.09-3.13) [30]
jealous delusion	1,45	2.58 (1.98-3.02) [30]
restlessness	1,40	0.69 (0.07-1.13) [29]
disturbance in attention	1,40	1 (0.38-1.44) [29]
hypomania	1,40	2.6 (1.98-3.04) [29]
bipolar disorder	1,36	2.2 (1.57-2.64) [28]
thinking abnormal	1,36	1.91 (1.28-2.36) [28]
withdrawal syndrome	1,31	1.35 (0.71-1.8) [27]
depressed mood	1,31	0.95 (0.31-1.4) [27]
major depression	1,26	2.69 (2.03-3.15) [26]
anger	1,21	2.04 (1.37-2.51) [25]
paranoia	1,21	1.54 (0.87-2.01) [25]
marital problem	1,11	3.3 (2.61-3.79) [23]
anhedonia	1,11	2.09 (1.39-2.58) [23]
product use in unapproved indication	1,11	0.78 (0.09-1.27) [23]
emotional disorder	1,06	1.48 (0.76-1.98) [22]
mental impairment	1,02	1.52 (0.79-2.03) [21]

Table S7. Nodes with highest degree-centrality.

		Aripiprazole					
Ising		Phi		PPMI	PPMI		
economic problem 24 irritability			49	overwork	97		
gambling disorder	20	anxiety	47	pyromania	89		
mental disorder	16	product use in unapproved indication	44	kleptomania	85		
obsessive-compulsive disorder	16	suicide attempt	41	poriomania	60		
compulsive shopping	15	obsessive-compulsive disorder	39	anxiety	45		
Fatigue	15	depression	38	product use in unapproved indication	43		
depressed mood	15	economic problem	38	suicide attempt	39		
Insomnia	15	insomnia	35	obsessive-compulsive disorder	39		
impulsivity	14	suicidal ideation	35	economic problem	38		
emotional distress	13	asthenia	34	gambling disorder	37		

Pramipexole						
Ising		Phi		PPMI		
gambling disorder	10	mental disorder	20	pyromania	60	
emotional distress	9	agitation	18	poriomania	57	
Dyskinesia	7	anxiety	14	gaming disorder	55	
Anxiety	7	bipolar disorder	14	excessive exercise	48	
depression	7	cognitive disorder	14	kleptomania	47	
emotional disorder	6	crying	14	body-focused disorder	39	
stereotypy	6	depression	14	paranoia	32	
mental disorder	5	insomnia	14	emotional disorder	31	
cognitive disorder	5	apathy	13	mental impairment	31	
drug withdrawal				product use in unapproved		
syndrome	5	abnormal behaviour	12	indication	30	

Table S8. Aripiprazole edges. The ten strongest links for the three networks of aripiprazole are shown. Note that the links are undirected, therefore the two nodes may be switched.

_	Ising			φ	•		PPMI	
antipsychotic drug level below therapeutic	8.21	therapeutic product effect variable	antipsychotic drug level below therapeutic	0.99	therapeutic product effect variable	overwork	8.84	pyromania
theft	7.26	shoplifting	antipsychotic drug level below therapeutic	0.95	toxicity	kleptomania	8.33	overwork
therapeutic product effect incomplete	6.18	therapeutic product effect variable	therapeutic product effect variable	0.94	toxicity	overwork	7.08	poriomania
toxicity to various agents	6	antipsychotic drug level below therapeutic	antipsychotic drug level below therapeutic	0.93	leukopenia	kleptomania	6.96	pyromania
mental impairment	4.96	social problem	leukopenia	0.92	therapeutic product effect variable	antipsychotic drug level below therapeutic	5.95	therapeutic product effect variable
obesity	4.32	dyslipidaemia	shoplifting	0.91	theft	antipsychotic drug level below therapeutic	5.89	leukopenia
therapeutic product effect incomplete	4.16	toxicity to various agents	leukopenia	0.89	toxicity	leukopenia	5.89	therapeutic product effect variable
suicide attempt	4.16	suicidal ideation	therapeutic product effect incomplete	0.83	therapeutic product effect variable	muscle twitching	5.84	personality disorder
euphoric mood	4.1	antipsychotic drug level below therapeutic	therapeutic product effect incomplete	0.82	toxicity	antipsychotic drug level below therapeutic	5.81	toxicity to various agents
gastrooesopha geal reflux disease	3.99	migraine	antipsychotic drug level below therapeutic	0.82	therapeutic product effect incomplete	therapeutic product effect variable	5.81	toxicity to various agents

Table S9. Pramipexole edges. The ten strongest links for the three networks of pramipexole are shown. Note that the links are undirected, therefore the two nodes may be switched.

	Ising			φ			PPMI	
body-focused disorder	3.11	kleptomania	emotional distress	0.56	pain	poriomania	8.82	pyromania
mental impairment	3.09	mental disorder	emotional distress	0.55	OCD	gaming disorder	8.39	pyromania
on and off phenomenon	3.05	dyskinesia	hyperphagia	0.5	weight increased	gaming disorder	7.8	poriomania
hyperphagia	2.67	weight increased	anxiety	0.48	fear	excessive exercise	7.32	pyromania
paranoia	2.66	psychotic disorder	anxiety	0.47	stress	kleptomania	7.32	pyromania
anxiety	2.61	fear	anxiety	0.43	depression	excessive exercise	6.74	poriomania
jealous delusion	2.46	marital problem	depression	0.41	stress	kleptomania	6.74	poriomania
pain	2.36	emotional distress	fear	0.41	pain	paranoia	6.39	pyromania
cognitive disorder	2.36	emotional disorder	mental disorder	0.39	mental impairment	excessive exercise	3.3	gaming disorder
depressed mood	2.3	anhedonia	dyskinesia	0.38	on and off phenomenon	gaming disorder	3.3	kleptomania

Table S10. Aripiprazole clusters obtained from Ising and Phi estimation. Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similarities with Phi.

Ising		PHI	PPMI
	Hypersomnia; sleep disorder; insomnia; somnolence	Hypersomnia; sleep disorder; insomnia	Hypersomnia; sleep disorder; insomnia
	Fatigue; asthenia; feeling abnormal	Fatigue; asthenia; feeling abnormal	Fatigue; asthenia; feeling abnormal
	Constipation	Constipation; abdominal pain	Constipation; abdominal pain
	Decreased appetite; weight decreased	Decreased appetite	Decreased appetite
	Panic attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania	Panick attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania; affective disorder	Panick attack; stress; bipolar disorder; crying; depressed mood; depression; apathy; mood swings; mania; affective disorder
	Aggression; anger; irritability	Aggression; anger	Aggression; anger
	Psychomotor hyperactivity; restlessness; agitation	Psychomotor hyperactivity; restlessness; agitation	Psychomotor hyperactivity; restlessness; agitation
	Abnormal behaviour	Abnormal behaviour; thinking abnormal	Abnormal behaviour; thinking abnormal
	Myalgia	Myalgia; arthralgia; back pain	Myalgia; arthralgia; back pain
	Drug dependence	Drug dependence; dependence	Drug dependence; dependence
	Disturbance in attention; memory impairment	Disturbance in attention; amnesia; cognitive disorder	Disturbance in attention; amnesia; cognitive disorder
	Hallucination, auditory	Hallucination, auditory; paranoia	Hallucination, auditory; paranoia
impu	I lsivity Paraphilia; stereotypy	Paraphilia; stereotypy; kleptomania; poriomania	Paraphilia; stereotypy; kleptomania; poriomania; overwork; pyromania
	Headache	Cough	Cough
		Loss of personal independence in daily activities	Loss of personal independence in daily activities
		Hospitalisation	Hospitalisation
		Prescribed underdose; prescribed overdose	Prescribed underdose; incorrect dose administered
Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased		Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased	Blood triglycerides increased; low density lipoprotein increased; blood cholesterol increased; blood glucose increased; alanine aminotransferase increased; hunger; sleep apnoea syndrome; gastrointestinal surgery
	Fear; affective disorder	Fear	Fear
	Personal relationship issue; social problem	Personal relationship issue; social problem; theft; shoplifting; Disability; economic problem; bankruptcy; divorced; homeless; loss of employment	Personal relationship issue; social problem; theft; shoplifting; Disability; economic problem; bankruptcy; divorced; homeless; loss of employment
	Mental impairment	Mental impairment	Mental impairment

	Pain	Pain	Pain
	Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety	Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety	Emotional distress; anhedonia; neuropsychiatric symptoms; anxiety
	Mental disorder	Mental disorder	Mental disorder
1	Injury; brain injury	Injury; brain injury	Injury; brain injury
	Disability; economic problem; bankruptcy; divorced; homeless; loss of employment		
compu	ulsivity Gambling disorder; Isive shopping; body-focused disorder; Isive hoarding; hypersexuality; impulsivity	Gambling disorder; compulsive shopping; body-focused disorder; compulsive hoarding; hypersexuality; impulsivity	Gambling disorder; compulsive shopping; body-focused disorder; compulsive hoarding; hypersexuality
	Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease	Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease	Unintended pregnancy; sexual dysfunction; psychosexual disorder; sexually transmitted disease
	Obsessive-compulsive disorder	Obsessive-compulsive disorder	
	Eating disorder; gastrointestinal surgery	Eating disorder; gastrointestinal surgery	Eating disorder
	Condition aggravated	Condition aggravated	Condition aggravated
	Product used in unapproved indication	Product used in unapproved indication	Product used in unapproved indication
	Theft; shoplifting	_	
	Suicidal ideation; suicide attempt	Suicidal ideation; suicide attempt	Suicidal ideation
therape	Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents	Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose	Therapeutic product effect incomplete; therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose
therape	therapeutic product effect variable; antipsychotic drug level below	therapeutic product effect variable; antipsychotic drug level below therapeutic;	therapeutic product effect variable; antipsychotic drug level below therapeutic;
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose
therapo	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased;	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood Hunger; hyperphagia; weight increased Obesity; dyslipidaemia; hypertension;	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood Hunger; hyperphagia; weight increased Obesity; dyslipidaemia; hypertension; sleep apnoea syndrome	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep apnoea syndrome	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Obesity; dyslipidaemia; hypertension
therapa therapa	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood Hunger; hyperphagia; weight increased Obesity; dyslipidaemia; hypertension; sleep apnoea syndrome Akathisia	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep apnoea syndrome	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Obesity; dyslipidaemia; hypertension Akathisia
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood Hunger; hyperphagia; weight increased Obesity; dyslipidaemia; hypertension; sleep apnoea syndrome Akathisia Sedation	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep apnoea syndrome	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Obesity; dyslipidaemia; hypertension Akathisia
therape	therapeutic product effect variable; antipsychotic drug level below eutic; toxicity to various agents Leukopenia Euphoric mood Hunger; hyperphagia; weight increased Obesity; dyslipidaemia; hypertension; sleep apnoea syndrome Akathisia Sedation	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Hunger; hyperphagia; weight increased; obesity; dyslipidaemia; hypertension; sleep apnoea syndrome Akathisia	therapeutic product effect variable; antipsychotic drug level below therapeutic; toxicity to various agents; prescribed overdose Leukopenia Euphoric mood Obesity; dyslipidaemia; hypertension Akathisia

	Diarrhoea; dyspepsia; gastroesophageal	Diarrhoea; dyspepsia; gastroe	esophageal reflux Diarrhoea; dyspepsia; gastroesophageal reflux
	reflux disease; abdominal pain	disease	disease
	Hypoaesthesia	Hypoaesthesia	Hypoaesthesia
	Poor quality sleep; nightmare	Poor quality sleep; nightmare	Poor quality sleep; nightmare; sedation; somnolence
	Hyperidrosis	Hyperidrosis	Hyperidrosis
	Migraine	Migraine; headache	Migraine; headache
	Muscle twitching; back pain; arthralgia	Muscle twitching	Muscle twitching
	Personality disorder	Personality disorder	Personality disorder
	Cough		
		Weight decreased	d Weight decreased
		Memory impairm	ent Memory impairment
		Irritability	Irritability
			Hyperphagia; weight increased
Isolated nodes: pyromania; overwork; incorrect dose administered; prescribed overdose; prescribed underdose; poriomania; dependence; thinking abnormal; hospitalisation; paranoia; kleptomania; loss of personal independence in daily activities		Isolated nodes: pyromania; of incorrect dose administered	verwork;

Table S11. Pramipexole clusters obtained from Ising and Phi estimation. Phi and Ising clusters are shown side by side. Ising clusters are color-coded, to show the similarities with Phi.

Ising	re color-coded, to show the similiar	PPMI
impulsivity Gambling disorder; compulsive shopping	Gambling disorder	Gambling disorder; compulsive shopping
Anxiety; depression; fear; emotional distress; stress	Anxiety; depression; fear; emotional distress; stress; major depression	Depression; fear; emotional distress; stress
Pain	Pain	
Obsessive-compulsive disorder	Obsessive-compulsive disorder	Obsessive-compulsive disorder
Suicidal ideation	Suicidal ideation; suicide attempt	Suicidal ideation
	Injury	
Hyperphagia; weight increased	Hyperphagia; weight increased	Hyperphagia; weight increased
Sleep disorder; somnolence; insomnia; disturbance in attention	Sleep disorder; somnolence	
Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome	Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome; drug dependence; drug abuse	Drug withdrawal syndrome; on and off phenomenon; dyskinesia; dopamine dysregulation syndrome; drug dependence; drug abuse; dependence
impulsivity Stereotypy; impulsivity; paraphilia	Stereotypy; impulsivity; paraphilia	Stereotypy; impulsivity; paraphilia; gaming disorder; poriomania; pyromania
Drug dependence; drug abuse		
Aggression	Aggression	Aggression
impulsivity Compulsive hoarding	Compulsive hoarding	Compulsive hoarding
	Paranoia; hallucination, visual; psychotic disorder	Hallucination, visual
	Psychomotor hyperactivity; restlessness	Psychomotor hyperactivity; restlessness
	Hypomania; mania	
	Eating disorder	Eating disorder
		Economic problem; abnormal behaviour
		Injury
		Personality change

			Somnolence
			Suicide attempt
	Bipolar disorder	Bipolar disorder; emotional disorder; apathy; crying	Bipolar disorder; emotional disorder; apathy; crying; anxiety
	Mental impairment; mental disorder	Mental impairment; mental disorder; cognitive disorder; disturbance in attention	Mental impairment; mental disorder; cognitive disorder; disturbance in attention
	Abnormal behaviour	Abnormal behaviour	
	Economic problem		
	Product use in unapproved indication	Overdose	Overdose
	Injury		
	Anhedonia; depressed mood; emotional disorder; apathy		
	Cognitive disorder		
	Overdose		
	Suicide attempt		
	Delusion		
(F)	Agitation	Agitation	Agitation
	Crying		
	Irritability	Insomnia	Insomnia
	Jealous delusion; paranoia; hallucination, visual; psychotic disorder	Jealous delusion	Jealous delusion; marital problem; paranoia; psychotic disorder; delusion
impul	Sivity Hypersexuality	Hypersexuality; excessive exercise; compulsive shopping	Hypersexuality; excessive exercise; body- focused disorder; kleptomania
	Marital problem	Marital problem;	
TE STATE OF THE ST	Psychomotor hyperactivity		
	Hypomania; mania	Anhedonia; depressed mood	Hypomania; mania; anhedonia; depressed mood; major depression

	Irritability; anger	Irritability; anger
	Dependence; withdrawal syndrome	Withdrawal syndrome
	Thinking abnormal	Thinking abnormal
impulsivity body-focused	body-focused disorder; kleptomania	
disorder; kleptomania		Compulsions
		Product use in unapproved indication
		Sudden onset of sleep; sleep disorder
Isolated nodes: poriomania;	Isolated nodes: poriomania;	
compulsions; personality change;	compulsions; personality change;	
gaming disorder; eating disorder;	gaming disorder	
sudden onset of sleep; restlessness;		
pyromania; thinking abnormal;		
withdrawal syndrome; excessive		
exercise; anger; dependence; major		
depression		




Figure S1. The secondary impact of aripiprazole-induced pathologic impulsivity. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated, after rescaling them from 0 to 1.




Figure S2. The secondary impact of aripiprazole-induced pathologic impulsivity, Ising estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Ising estimation. The layout is calculated using a spring model with, as weight, the links from the Ising.




Figure S3. The secondary impact of aripiprazole-induced pathologic impulsivity, Phi estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Phi estimation.

The layout is calculated using a spring model with, as weight, the links from the Phi.




Figure S4. The secondary impact of aripiprazole-induced pathologic impulsivity, PPMI estimation. The network shows the events disproportionally reported with aripiprazole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.




Figure S5. The secondary impact of pramipexole-induced pathologic impulsivity. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the three methods: Ising (A), Phi (B) and PPMI (C). The layout is calculated using a spring model with, as weight, the average of the three weights calculated, after rescaling them from 0 to 1.




Figure S6. The secondary impact of pramipexole-induced pathologic impulsivity, Ising estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Ising estimation. The layout is calculated using a spring model with, as weight, the links from the Ising.




Figure S7. The secondary impact of pramipexole-induced pathologic impulsivity, Phi estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the Phi estimation. The layout is calculated using a spring model with, as weight, the links from the Phi.




Figure S8. The secondary impact of pramipexole-induced pathologic impulsivity, PPMI estimation. The network shows the events disproportionally reported with pramipexole-related impulsivity. Impulsivity is shown as squares, other events as circles. Node colors and contours identify the clusters for the PPMI estimation. The layout is calculated using a spring model with, as weight, the links from the PPMI.




Figure S9. Degree centrality, pramipexole.






Figure S10. Degree centrality, aripiprazole.




Clusters PPMI Clusters PHI

Figure S11. Sankey showing comparison between clusters in PPMI and PHI, pramipexole.




Clusters PPMI Clusters ISING

Figure S12. Sankey showing comparison between clusters in PPMI and Ising, pramipexole.




Clusters PHI Clusters ISING

Figure S13. Sankey showing comparison between clusters in Phi and Ising, pramipexole.




Clusters PPMI Clusters PHI

Figure S14. Sankey showing comparison between clusters in PPMI and PHI, aripiprazole.



Clusters PPMI Clusters ISING

Figure S15. Sankey showing comparison between clusters in PPMI and Ising, aripiprazole.



Clusters PHI Clusters ISING

Figure S16. Sankey showing comparison between clusters in PHI and Ising, aripiprazole.